[1]       World Health Organization, “Health topics: Antimicrobial resistance,” World Health Organization. [Online]. Available: https://www.who.int/westernpacific/health-topics/antimicrobial-resistance#:~:text=Single%2C isolated interventions have limited,medicines%2C vaccines and diagnostic tools.

[2]       D. Cascioferro S, Schillaci, “The Future of Antibiotic: From the Magic Bullet to the Smart Bullet,” J Microb Biochem Technol, vol. 06, no. 05, 2014, doi: 10.4172/1948-5948.1000e118.

[3]       W. A. Adedeji, “THE TREASURE CALLED ANTIBIOTICS.,” Ann Ib Postgrad Med, vol. 14, no. 2, pp. 56–57, Dec. 2016, [Online]. Available: http://www.ncbi.nlm.nih.gov/pubmed/28337088

[4]       CDC, “Life Expectancy,” National Centre for Health Statistics.

[5]       World Health Organization, “Antimicrobial resistance: Key facts,” World Health Organization. [Online]. Available: https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance

[6]       C. Llor and L. Bjerrum, “Antimicrobial resistance: risk associated with antibiotic overuse and initiatives to reduce the problem.,” Ther Adv Drug Saf, vol. 5, no. 6, pp. 229–41, Dec. 2014, doi: 10.1177/2042098614554919.

[7]       F. Ching, “Bird Flu, SARS and Beyond,” in 130 Years of Medicine in Hong Kong, Singapore: Springer Singapore, 2018, pp. 381–434. doi: 10.1007/978-981-10-6316-9_14.

[8]       C. Manyi-Loh, S. Mamphweli, E. Meyer, and A. Okoh, “Antibiotic Use in Agriculture and Its Consequential Resistance in Environmental Sources: Potential Public Health Implications.,” Molecules, vol. 23, no. 4, Mar. 2018, doi: 10.3390/molecules23040795.

[9]       C. L. Ventola, “The antibiotic resistance crisis: part 1: causes and threats.,” P T, vol. 40, no. 4, pp. 277–83, Apr. 2015, [Online]. Available: http://www.ncbi.nlm.nih.gov/pubmed/25859123

[10]     F. Prestinaci, P. Pezzotti, and A. Pantosti, “Antimicrobial resistance: a global multifaceted phenomenon.,” Pathog Glob Health, vol. 109, no. 7, pp. 309–18, 2015, doi: 10.1179/2047773215Y.0000000030.

[11]     Centers for Disease Control and Prevention, “Antimicrobial Resistance Questions and Answers,” Centers for Disease Control and Prevention. U.S. Department of Health & Human Services.

[12]     J. A. Ayukekbong, M. Ntemgwa, and A. N. Atabe, “The threat of antimicrobial resistance in developing countries: causes and control strategies.,” Antimicrob Resist Infect Control, vol. 6, p. 47, 2017, doi: 10.1186/s13756-017-0208-x.

[13]     World Health Organization, “World Health Day 2011 Regulate and promote rational use of medicines, including in animal husbandry, and ensure proper patient care,” WHO Regional Office for the Eastern Mediterranean. [Online]. Available: https://www.emro.who.int/world-health-days/2011/regulate-and-promote-rational-use-of-medicines-including-in-animal-husbandry-and-ensure-proper-patient-care.html

[14]     One Health Trust, “Global livestock antibiotic use expected to increase 67% by 2030,” One Health Trust (OHT).

[15]     S. Cecchini, M. Langer, J. Luke, “ANTIMICROBIAL RESISTANCE IN G7 COUNTRIES AND BEYOND: Economic Issues, Policies and Options for Action,” 2015.

[16]     World Health Organization, “Lack of new antibiotics threatens global efforts to contain drug-resistant infections,” World Health Organization.

[17]     HM Government, “Tackling antimicrobial resistance 2019–2024,” 2019.

[18]     J. Davies and D. Davies, “Origins and evolution of antibiotic resistance.,” Microbiol Mol Biol Rev, vol. 74, no. 3, pp. 417–33, Sep. 2010, doi: 10.1128/MMBR.00016-10.

[19]     J. O’NEIL, “Tackling drug-resistant infections globally: final report and recommendations the review on antimicrobial resistance chaired by JIM O’NEILL; 2016.,” 2016. [Online]. Available: https://amr-review.org/sites/default/files/160518_Final paper_with cover.pdf

[20]     P. Dadgostar, “Antimicrobial Resistance: Implications and Costs.,” Infect Drug Resist, vol. 12, pp. 3903–3910, 2019, doi: 10.2147/IDR.S234610.

[21]     European Centre for Disease Prevention and Control, “Surveillance of antimicrobial resistance in Europe – Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net) 2017,” Stockholm, 2018. [Online]. Available: https://www.ecdc.europa.eu/sites/default/files/documents/EARS-Net-report-2017-update-jan-2019.pdf

[22]     P. Shrestha et al., “Enumerating the economic cost of antimicrobial resistance per antibiotic consumed to inform the evaluation of interventions affecting their use,” Antimicrob Resist Infect Control, vol. 7, no. 1, p. 98, Aug. 2018, doi: 10.1186/s13756-018-0384-3.

[23]     J. S. Yu, R. N. Hansen, A. Valderrama, and J. J. Carlson, “Indirect costs and workplace productivity loss associated with non-Hodgkin lymphoma.,” Leuk Lymphoma, vol. 57, no. 11, pp. 2636–43, Nov. 2016, doi: 10.3109/10428194.2016.1161187.

[24]     Indian Council of Medical Research, “India’s Antimicrobial Resistance Surveillance & Research Initiative: AMRSN,” Division of Epidemiology and Communicable Diseases, Indian Council of Medical Research.

[25]     M. Haque et al., “Strategies to Prevent Healthcare-Associated Infections: A Narrative Overview.,” Risk Manag Healthc Policy, vol. 13, pp. 1765–1780, 2020, doi: 10.2147/RMHP.S269315.

[26]     Centers for Disease Control and Prevention, “Continuing Education and Informational Resources,” Centers for Disease Control and Prevention. U.S. Department of Health & Human Services.

[27]     S. Doron and L. E. Davidson, “Antimicrobial stewardship.,” Mayo Clin Proc, vol. 86, no. 11, pp. 1113–23, Nov. 2011, doi: 10.4065/mcp.2011.0358.

[28]     S. Ganesh Kumar, C. Adithan, B. N. Harish, S. Sujatha, G. Roy, and A. Malini, “Antimicrobial resistance in India: A review,” J Nat Sci Biol Med, vol. 4, no. 2, pp. 286–291, 2013, doi: 10.4103/0976-9668.116970.

[29]     I. A. Dutescu and S. A. Hillier, “Encouraging the Development of New Antibiotics: Are Financial Incentives the Right Way Forward? A Systematic Review and Case Study.,” Infect Drug Resist, vol. 14, pp. 415–434, 2021, doi: 10.2147/IDR.S287792.

[30]     M. M. Cowan, “Plant products as antimicrobial agents.,” Clin Microbiol Rev, vol. 12, no. 4, pp. 564–82, Oct. 1999, doi: 10.1128/CMR.12.4.564.

[31]     Wellcome Trust, “Q&A: Why is it so hard to develop new antibiotics?,” Wellcome Trust, London.

[32]     S. C. Lester, M. del P. Pla, F. Wang, I. P. Schael, H. Jiang, and T. F. O’Brien, “The Carriage of Escherichia coli Resistant to Antimicrobial Agents by Healthy Children in Boston, in Caracas, Venezuela, and in Qin Pu, China,” New England Journal of Medicine, vol. 323, no. 5, pp. 285–289, Aug. 1990, doi: 10.1056/NEJM199008023230501.

[33]     H. Goossens, “Antibiotic consumption and link to resistance,” Clinical Microbiology and Infection, vol. 15, pp. 12–15, Apr. 2009, doi: 10.1111/j.1469-0691.2009.02725.x.

[34]     SCENIHR, “Assessment of the Antibiotic Resistance Effects of Biocides, 19 January 2009,” Brussels, 2009. [Online]. Available: https://ec.europa.eu/health/ph_risk/committees/04_scenihr/docs/scenihr_o_021.pdf

[35]     Directorate General of Health Services, “NATIONAL POLICY FOR CONTAINMENT OF ANTIMICROBIAL RESISTANCE INDIA,” New Delhi, 2011.

[36]     B. Aslam et al., “Antibiotic resistance: a rundown of a global crisis.,” Infect Drug Resist, vol. 11, pp. 1645–1658, 2018, doi: 10.2147/IDR.S173867.

[37]     S. Knobler, S. Lemon, and et al. Najafi M, “Factors Contributing to the Emergence of Resistance,” in The Resistance Phenomenon in Microbes and Infectious Disease Vectors - NCBI Bookshelf, National Academies Press (US), 2003.

[38]     A. Bezoen, W. van Haren, and JC. Hanekamp, “Emergence of a Debate: AGPs and Public Health Human Health and Antibiotic Growth Promoters (AGPs): Reassessing the Risk,” 1999.

[39]     FAAIR Scientific Advisory Panel, “Policy Recommendations,” Clinical Infectious Diseases, vol. 34, no. s3, pp. S76–S77, Jun. 2002, doi: 10.1086/340243.

[40]     J. L. Martinez, “Environmental pollution by antibiotics and by antibiotic resistance determinants,” Environmental Pollution, vol. 157, no. 11, pp. 2893–2902, Nov. 2009, doi: 10.1016/j.envpol.2009.05.051.

[41]     H. Eagar, G. Swan, and M. Van Vuuren, “A survey of antimicrobial usage in animals in South Africa with specific reference to food animals,” J S Afr Vet Assoc, vol. 83, no. 1, Aug. 2012, doi: 10.4102/jsava.v83i1.16.

[42]     A. Kotwani, J. Joshi, and A. S. Lamkang, “Over-the-Counter Sale of Antibiotics in India: A Qualitative Study of Providers’ Perspectives across Two States.,” Antibiotics (Basel), vol. 10, no. 9, Sep. 2021, doi: 10.3390/antibiotics10091123.

[43]     V. Tikhute, “Crimes Against Children in India: Regional Patterns and Annual Trends,” 1, Oct. 2023. doi: 10.33774/COE-2023-K02LZ.

[44]     R. R. Uchil, G. S. Kohli, V. M. Katekhaye, and O. C. Swami, “Strategies to combat antimicrobial resistance.,” J Clin Diagn Res, vol. 8, no. 7, pp. ME01-4, Jul. 2014, doi: 10.7860/JCDR/2014/8925.4529.

[45]     R. Samuel, A. M. Almedom, G. Hagos, S. Albin, and A. Mutungi, “Promotion of handwashing as a measure of quality of care and prevention of hospital-acquired infections in Eritrea: the Keren study.,” Afr Health Sci, vol. 5, no. 1, pp. 4–13, Mar. 2005, [Online]. Available: http://www.ncbi.nlm.nih.gov/pubmed/15843125

[46]     N. C. Sharma, P. K. Mandal, R. Dhillon, and M. Jain, “Changing profile of Vibrio cholerae O1, O139 in Delhi & its periphery (2003-2005).,” Indian J Med Res, vol. 125, no. 5, pp. 633–40, May 2007, [Online]. Available: http://www.ncbi.nlm.nih.gov/pubmed/17642498

[47]     S. Arora Ray, S. Saha, and M. Bal, “Imipenem-resistance among multi-drug resistant clinical strains in urinary infections from Kolkata.,” Indian J Med Res, vol. 125, no. 5, pp. 689–91, May 2007, [Online]. Available: http://www.ncbi.nlm.nih.gov/pubmed/17642506

[48]     A. Jain and R. Mondal, “Prevalence & antimicrobial resistance pattern of extended spectrum beta-lactamase producing Klebsiella spp isolated from cases of neonatal septicaemia.,” Indian J Med Res, vol. 125, no. 1, pp. 89–94, Jan. 2007, [Online]. Available: http://www.ncbi.nlm.nih.gov/pubmed/17332661

[49]     G. A. Menezes, B. N. Harish, S. Sujatha, K. Vinothini, and S. C. Parija, “Emergence of vancomycin-intermediate Staphylococcus species in southern India.,” J Med Microbiol, vol. 57, no. Pt 7, pp. 911–912, Jul. 2008, doi: 10.1099/jmm.0.47829-0.

[50]     C. A. Chande, S. N. Shrikhande, D. L. Jain, S. Kapale, H. Chaudhary, and R. M. Powar, “Prevalence of methicillin-resistant Staphylococcus aureus nasopharyngeal carriage in children from urban community at Nagpur.,” Indian J Public Health, vol. 53, no. 3, pp. 196–8, 2009, [Online]. Available: http://www.ncbi.nlm.nih.gov/pubmed/20108888

[51]     A. Manoharan, S. Chatterjee, D. Mathai, and SARI Study Group, “Detection and characterization of metallo beta lactamases producing Pseudomonas aeruginosa.,” Indian J Med Microbiol, vol. 28, no. 3, pp. 241–4, 2010, doi: 10.4103/0255-0857.66486.

[52]     M. S. Shenoy, G. K. Bhat, A. Kishore, and M. K. Hassan, “Significance of MRSA strains in community associated skin and soft tissue infections.,” Indian J Med Microbiol, vol. 28, no. 2, pp. 152–4, 2010, doi: 10.4103/0255-0857.62494.